Valuation Oramed Pharmaceuticals Inc. Deutsche Boerse AG
Stocks
OJU1
US68403P2039
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
20:39:56 01/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.960 EUR | -2.94% |
|
-0.25% | +68.74% |
| 09-21 | Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to S&P Global BMI Index | CI |
| 09-01 | Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO | MT |
Company Valuation: Oramed Pharmaceuticals Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 543.9 | 470.6 | 93.18 | 97.56 | 113.4 | 194.3 |
| Change | - | -13.48% | -80.2% | 4.69% | 16.28% | 71.25% |
| Enterprise Value (EV) | 543.9 | 470.6 | 93.18 | 97.56 | 113.4 | 194.3 |
| Change | - | -13.48% | -80.2% | 4.69% | 16.28% | 71.25% |
| P/E | -46.1x | -12.8x | 16.5x | -5.04x | 1.9x | 1.04x |
| PBR | - | - | - | - | - | - |
| PEG | - | -0x | -0x | 0x | -0x | 0x |
| Capitalization / Revenue | 602x | 174x | 69.5x | - | 56.7x | - |
| EV / Revenue | 0x | 0x | 0x | - | 0x | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | - | -0x | -0x | -0x | -0x | -8.41x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.31 | -0.94 | 0.14 | -0.48 | 1.5 | 4.47 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.904 | 2.703 | 1.34 | - | 2 | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -40.6 | -15.77 | -12.78 | -15.09 | -23.1 |
| Net income 1 | - | -36.56 | 5.525 | -19.06 | 64.05 | 188.6 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 14.280 | 12.030 | 2.310 | 2.420 | 2.850 | 4.670 |
| Nbr of stocks (in thousands) | 38,086 | 39,115 | 40,339 | 40,312 | 39,802 | 41,597 |
| Announcement Date | 30/03/22 | 06/03/23 | 06/03/24 | 27/03/25 | 26/03/26 | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.73x | 7.77x | 15.61x | 1.37% | 74.46B | |
| 31.25x | 9.01x | 28.06x | 0.04% | 60.14B | |
| 33.64x | 6.03x | 18.07x | 0.97% | 48.15B | |
| 34.63x | 3.34x | 14.4x | -.--% | 44.25B | |
| -21.16x | 229.18x | -22.81x | -.--% | 43.99B | |
| 47.94x | 5.54x | 30.43x | -.--% | 41.61B | |
| 26.89x | 7.76x | 19.96x | 0.42% | 29.97B | |
| 33.91x | 7.26x | 18.84x | -.--% | 29.31B | |
| -70.02x | 13.44x | -68.51x | -.--% | 24.93B | |
| Average | 15.42x | 32.15x | 6.01x | 0.31% | 44.09B | |
| Weighted average by Cap. | 19.58x | 31.88x | 10.24x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ORMP Stock
- OJU1 Stock
- Valuation Oramed Pharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
